{
    "key_points": [
        "Pfizer data indicates a third dose of its Covid-19 vaccine significantly increases antibody levels against the Delta variant compared to just two doses.",
        "Antibody levels against Delta variant increased fivefold in people aged 18 to 55 and 11-fold in people aged 65 to 85 after a third dose.",
        "The study involved tests on 23 people and the data have not been peer-reviewed or published.",
        "Dr. Mikael Dolsten announced the data during Pfizer's earnings call, highlighting the potential high increase in neutralizing antibodies post third dose.",
        "New safety and efficacy data indicate the vaccine's overall efficacy stands at about 91% for up to six months after the second dose.",
        "Pfizer plans to submit data for emergency use authorization of a third dose to the FDA as early as next month.",
        "The FDA and CDC have previously stated Americans do not currently need a third dose.",
        "US Surgeon General Dr. Vivek Murthy reaffirmed that people do not need a booster shot at this moment.",
        "Questions remain about the correlation between antibody levels and real-world immunity, as well as the role of other parts of the immune system.",
        "Debate continues over the ethics of administering booster shots in developed countries while there is a vaccine shortage in the developing world."
    ],
    "spokespersons": [
        "Dr. Mikael Dolsten (Leads worldwide research, development, and medical for Pfizer)",
        "Dr. Vivek Murthy (US Surgeon General)"
    ],
    "article_type": "general reporting",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}